Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L, van Zandwijk N (1997) J Clin Oncol 15: 285-91 Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, De Vore RF (1996) J Clin Oncol 14: 2054-60 Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D (2010) J Clin Oncol 28: 1843-9 BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ (2012) J Clin Oncol 30: 34-41 Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R (2001) J Clin Oncol 19: 634-44 Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D, Bunin GR, Meadows AT (2000) J Clin Oncol 18: 12-7 Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, McCloskey T (1994) J Clin Oncol 12: 176-83 Copy number polymorphisms and anticancer pharmacogenomics. Gamazon ER, Huang RS, Dolan ME, Cox NJ (2011) Genome Biol 12: R46 Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C (2007) Cancer Res 67: 1176-83 Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Dolan ME (2011) Clin Cancer Res 17: 5490-500 High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Stiff PJ, Bayer R, Tan S, Camarda M, Sosman J, Peace D, Kinch L, Rad N, Loutfi S (1995) Clin Cancer Res 1: 1495-502 A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H (2009) Clin Cancer Res 15: 2158-65 Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L (2017) Ann Oncol 28: 777-783 Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS (2012) Mol Cancer Ther 11: 2054-61 Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Gamazon ER, Im HK, O'Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS (2011) Mol Cancer Ther 10: 472-80 A randomized Phase II trial in patients with carcinoma of an unknown primary site. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR (2001) Cancer 91: 592-7 Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME (2013) Pharmacogenomics J 13: 35-43 Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, Shyr Y, Cmelak AJ (2010) Int J Radiat Oncol Biol Phys 77: 468-76 A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Choy H, Devore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) Int J Radiat Oncol Biol Phys 47: 931-7 Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, Choy H (1999) Int J Radiat Oncol Biol Phys 44: 399-405 Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials. DeVore RF, Jagasia M, Johnson DH (1997) Semin Oncol 24: S12-27-S12-29 Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Johnson DH, Paul DM, Hande KR, DeVore R (1996) Semin Oncol 23: 42-6 Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, LaPorte K, Johnson DH (1997) Semin Oncol 24: S12-21-S12-26 Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46. Johnson DH, Paul DM, Hande KR, DeVore RF (1995) Semin Oncol 22: 30-3 Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Johnson DH, DeVore R, Greco FA, Walls J, Thomas M, Hande KR, Hainsworth JD (1992) Semin Oncol 19: 50-6 Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. Vlacich G, Diaz R, Thorpe SW, Murphy BA, Kirby W, Sinard RJ, Shakhtour B, Shyr Y, Murphy P, Netterville JL, Yarbrough WG, Cmelak AJ (2012) Oncologist 17: 673-81 A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D (1995) Gynecol Oncol 57: 278-85 Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Gynecol Oncol 100: 330-7 Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, Dolan ME (2011) PLoS One 6: e21920 Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, Friedman DL, Naduvilath TJ (2002) Am J Ophthalmol 133: 657-64 Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. O'Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, Stephanie Huang R, Eileen Dolan M (2010) Pharmacogenet Genomics 20: 327-37 Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA (2000) J Thorac Cardiovasc Surg 119: 429-39 Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Siegenthaler MP, Pisters KM, Merriman KW, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Smythe WR, Putnam JB (2001) Ann Thorac Surg 71: 1105-11; discussion 1111-2 Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA (2004) Ann Thorac Surg 78: 1152-60; discussion 1152-60 Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach. Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, Santapuram PR, Tao YK, Boyd KL, Himmel LE, Chen SC, Du L, Friedman DL, Richmond A (2019) Invest Ophthalmol Vis Sci 60: 954-964 Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt PA, Slovis B, Laporte K, Shyr Y, Johnson DH (2001) Lung Cancer 34: 441-9 The role of radiation, with or without chemotherapy, in the management of NSCLC. Chakravarthy A, Johnson D, Choy H (1999) Oncology (Williston Park) 13: 93-100 Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Silver HJ, Dietrich MS, Murphy BA (2007) Head Neck 29: 893-900 Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin. Williams LL, Fudge M, Burnett LS, Jones HW (1992) Am J Clin Oncol 15: 331-6 Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Johnson DH, Hainsworth JD, DeVore R, Hande KR, Greco FA (1992) Oncology 49 Suppl 1: 57-61; discussion 61-2
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.